CAMBRIDGE, Mass. (AP) _ Alnylam Pharmaceuticals Inc. (ALNY) on Thursday reported a loss of $405.9 million in its third quarter.

The Cambridge, Massachusetts-based company said it had a loss of $3.32 per share.

The results did not meet Wall Street expectations. The average estimate of 11 analysts surveyed by Zacks Investment Research was for a loss of $1.86 per share.

The RNA interference drug developer posted revenue of $264.3 million in the period, which also did not meet Street forecasts. Ten analysts surveyed by Zacks expected $285.3 million.

Alnylam shares have climbed 19% since the beginning of the year. The stock has climbed nearly 2% in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ALNY at https://www.zacks.com/ap/ALNY

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News